Previously reported criteria and amplification rates of Her-2/neu in prostate cancer
| First author | Patient numbers | Probe | Criteria for amplification | % Amplified |
|---|---|---|---|---|
| Ross5 | 113 | Quantum Appligene | ≥5 signals in ≥20% | 41% |
| Mark6 | 86 | Vysis | Ratio ≥1.5 | 9% |
| Bubendorf12 | 262 tumour microarrays | Vysis | Ratio ≥3 | 0% |
| Oxley | 114 | Quantum Appligene | ≥5 signals in ≥20% | 1.75% |
| Ratio ≥2 | 0% |
CiteULike
Connotea
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
Technorati
Twitter
Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of
JCP.
View free sample issue >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Online ISSN 1472-4146
Copyright © 2012 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists. All rights reserved.
